Combination Therapy of Statins with Ezetimibe

Authors: Moriguchi, Emilio H.; Vieira, Jose Luiz d. C.

Source: Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Immunology, Endocrine and Metabolic Agents), Volume 8, Number 2, June 2008 , pp. 189-190(2)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

OR

Price: $71.00 plus tax (Refund Policy)

Abstract:

Ezetimibe is a cholesterol absorption inhibitors that blocks the intestinal absorption of cholesterol and biliary cholesterol without affecting the uptake of triglyceride or fat-soluble vitamins. The co-administration of ezetimibe with statin has been shown to produce significant incremental reduction in LDL-C beyond that achieved with statin therapy alone. The efficacy and safety of this strategy has been studied in a several trials in a great number of patients. The mean difference between treatments significantly favoured the ezetimibe/statin combination over placebo/statin for total cholesterol (p < 0.0001), LDL-C (p < 0.0001) and HDL-C (p < 0.0001). The probability of reaching the LDL-C treatment goal was significantly higher for patients on ezetimibe/statin relative to those on placebo/ statin (p < 0.0001). Elevations in creatine kinase, alanine aminotransferase or aspartate aminotransferase that were considered as an adverse effect did not differ significantly between treatments. Ezetimibe co-administered with ongoing statin therapy provides significant additional lipid-lowering in patients not at LDL-C goal on statin therapy alone, allowing more patients to reach their LDL-C goal with no increment in the side-effects.





Keywords: Ezetimibe; HDL; LDL; cholesterol; meta-analysis; safety; statins

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/187152208784587953

Publication date: June 1, 2008

More about this publication?
  • Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in the medicinal chemistry and rational drug design for the discovery of new Immunology, Endocrine & Metabolic Agents. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Immunology, Endocrine & Metabolic medicinal chemistry.

    Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in Immunology, Endocrine & Metabolic drug discovery.
Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page